



CORRECTION

Correction to: Imaging Intensity and Survival Outcomes in High-Risk Resected Melanoma Treated by Systemic Therapy at Recurrence

Andrea Marie Ibrahim, MSc¹, Melanie Le May, MD, MSc², Dominick Bossé, MD, MSc, MPH, FRCPC³, Horia Marginean, MD, MS¹, Xinni Song, MD, FRCPC³, Carolyn Nessim, MD, MSc, FRCSC, FACS⁴, and Michael Ong, MD, FRCPC³

¹Cancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada; ²Division of Internal Medicine, University of Ottawa, The Ottawa Hospital, Ottawa, ON, Canada; ³Division of Medical Oncology, University of Ottawa, The Ottawa Hospital, Ottawa, ON, Canada; ⁴Division of General Surgery, University of Ottawa, The Ottawa Hospital, Ottawa, ON, Canada

CORRECTION TO: ANN SURG ONCOL
[HTTPS://DOI.ORG/10.1245/S10434-020-08407-8](https://doi.org/10.1245/S10434-020-08407-8)

In the original article, the survival curves are missing in Fig. 1c and d. Following is the corrected Fig. 1.

The original article can be found online at <https://doi.org/10.1245/s10434-020-08407-8>.

© Society of Surgical Oncology 2020
Published Online: 22 May 2020

M. Ong, MD, FRCPC
e-mail: mong@toh.ca




FIG. 1 Kaplan–Meier curves for recurrence and survival by symptom status at recurrence. **a** Recurrence-free survival stratified by AJCC stage. **b** Survival of patients treated with any systemic therapy for metastatic recurrence stratified by symptom status at recurrence [median survival 21.2 (ASDR) vs. 7.6 months (SR); HR 2.16, 95% CI 1.30–3.59; $p = 0.003$]. **c** Survival of patients treated with anti-PD1 therapy for metastatic recurrence, stratified by symptom status at recurrence [median not reached (ASDR) vs. 13.6

months (SR); HR 1.99, 95% CI 0.69–5.72; $p = 0.2$]. **d** OS from the start of surveillance stratified by symptom status at recurrence [median survival time 39.2 months (ASDR) vs. 23.2 months (SR); HR 1.59, 95% CI 1.10–2.31; $p = 0.02$]. OS overall survival, HR hazard ratio, CI confidence interval, AJCC American Joint Committee on Cancer, ASDR asymptomatic surveillance-detected recurrence, SR symptomatic recurrence, PDI programmed death receptor-1

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.